Spanish Breast Cancer Research Group
- Country
- 🇪🇸Spain
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 101
- Market Cap
- -
- Website
- https://www.geicam.org
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 166
- Registration Number
- NCT01875367
- Locations
- 🇪🇸
Hospital de Mataró, Mataró, Barcelona, Spain
🇪🇸Hospital de Manacor, Manacor, Illes Balears, Spain
🇪🇸Hospital General Universitario de Granollers, Granollers, Barcelona, Spain
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer
- Conditions
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 143
- Registration Number
- NCT01733628
- Locations
- 🇪🇸
Complejo Hospitalario de Jaén, Jaén, Spain
🇪🇸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
🇪🇸Hospital General Universitario de Alicante, Alicante, Spain
A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 26
- Registration Number
- NCT01598285
- Locations
- 🇪🇸
Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 83
- Registration Number
- NCT01565499
- Locations
- 🇪🇸
Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain
🇪🇸Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
🇪🇸Instituto Oncológico de Guipúzcoa, Donostia-San Sebastián, Guipúzcoa, Spain
Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
- Conditions
- First Posted Date
- 2011-06-21
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 236
- Registration Number
- NCT01377363
- Locations
- 🇪🇸
Hospital General de Elda, Elda, Alicante, Spain
🇪🇸Hospital de Sagunto, Sagunto, Valencia, Spain
🇪🇸Hospital Virgen de los Lirios, Alcoy, Alicante, Spain
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
- Conditions
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 37
- Registration Number
- NCT01306942
- Locations
- 🇪🇸
Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain
🇪🇸Instituto Catalán de Oncología de Barcelona (Hospital Duran i Reynalds), Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 212
- Registration Number
- NCT01298193
- Locations
- 🇪🇸
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 102
- Registration Number
- NCT00841828
- Locations
- 🇪🇸
Hospital General de Granollers, Granollers, Barcelona, Spain
🇪🇸Onkologikoa, Donostia-San Sebastián, Guipuzcoa, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 380
- Registration Number
- NCT00545077
- Locations
- 🇩🇪
Universitätsklinikum Essen, Essen, Germany
🇩🇪Klinikum Bayreuth, Bayreuth, Germany
🇩🇪Universitätsklinikum Charité, Berlin, Germany
Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 870
- Registration Number
- NCT00543127
- Locations
- 🇪🇸
Hospital de Sagunto, Sagunto, Valencia, Spain
🇪🇸Hospital Lluís Alcanyis, Xátiva, Valencia, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain